Capital One National Association reduced its holdings in Celgene Corporation (NASDAQ:CELG) by 2.7% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 46,654 shares of the biopharmaceutical company’s stock after selling 1,279 shares during the period. Capital One National Association’s holdings in Celgene Corporation were worth $6,059,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also modified their holdings of the company. Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of Celgene Corporation in the 1st quarter worth $118,000. Oakworth Capital Inc. grew its stake in shares of Celgene Corporation by 60.9% in the 1st quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 412 shares in the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its stake in shares of Celgene Corporation by 47.5% in the 1st quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 380 shares in the last quarter. Independent Portfolio Consultants Inc. grew its stake in shares of Celgene Corporation by 209.4% in the 1st quarter. Independent Portfolio Consultants Inc. now owns 1,541 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 1,043 shares in the last quarter. Finally, Schmidt P J Investment Management Inc. purchased a new position in shares of Celgene Corporation in the 1st quarter worth $201,000. 79.43% of the stock is owned by institutional investors and hedge funds.
Celgene Corporation (NASDAQ CELG) traded up 1.02% on Friday, hitting $142.04. 5,983,997 shares of the company traded hands. The stock’s 50-day moving average is $134.97 and its 200 day moving average is $127.46. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $142.69. The firm has a market capitalization of $111.12 billion, a P/E ratio of 43.99 and a beta of 1.89.
Celgene Corporation (NASDAQ:CELG) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.61 by $0.21. The firm had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm’s revenue was up 18.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.44 earnings per share. Equities analysts forecast that Celgene Corporation will post $7.33 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This article was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.chaffeybreeze.com/2017/09/17/capital-one-national-association-sells-1279-shares-of-celgene-corporation-celg.html.
A number of brokerages have commented on CELG. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $175.00 price objective on shares of Celgene Corporation in a research note on Wednesday, August 9th. Jefferies Group LLC reaffirmed a “buy” rating and set a $160.00 price target on shares of Celgene Corporation in a research note on Friday. Vetr raised shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 price target for the company in a research note on Wednesday, August 16th. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $150.00 price target on shares of Celgene Corporation in a research note on Friday, July 14th. Finally, Bank of America Corporation reaffirmed a “buy” rating on shares of Celgene Corporation in a research note on Wednesday. One research analyst has rated the stock with a sell rating, seven have given a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $149.34.
In related news, Director Michael D. Casey sold 9,250 shares of the firm’s stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $125.59, for a total value of $1,161,707.50. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Michael A. Friedman sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $132.50, for a total transaction of $1,325,000.00. Following the completion of the sale, the director now directly owns 5,000 shares in the company, valued at approximately $662,500. The disclosure for this sale can be found here. In the last ninety days, insiders sold 267,476 shares of company stock worth $35,812,841. 0.95% of the stock is owned by corporate insiders.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.